Alliance Pharma PLC on Tuesday reported a narrowed loss for 2024 despite a decline in revenue, due to a reduction in impairment charges.
The Chippenham, Wiltshire-based distributor of consumer healthcare brands and prescription medicines said its pretax loss narrowed to £14.5 million in 2024 from £48.8 million in 2023.
Revenue declined 1.1% to £178.8 million from £180.7 million, while cost of sales was reduced by 8.1% to £69.6 million from £75.7 million.
Alliance Pharma recorded an impairment of goodwill and intangible assets charge of £38.9 million for the year, down 51% on-year from £79.3 million. The group also delivered a one-off £2.0 million profit on the disposal of intangible assets.
The group declared no dividend for 2024, unchanged from 2023.
‘2024 has been an important year for Alliance as we implemented the necessary changes to accelerate decision making and to bring the consumer closer to the heart of the business,’ said Chief Executive Officer Nick Sedgwick.
‘I am delighted by the number of highly skilled senior managers that have joined Alliance, many of whom have already made a significant impact on the business, and I see further opportunity to deliver efficiency gains and capability improvements over time.’
Shares in Alliance Pharma were up 0.2% at 64.20 pence in London on Tuesday morning. The stock has risen 72% over the past year.
Copyright 2025 Alliance News Ltd. All Rights Reserved.